NIAID Initiates Trial of Experimental Avian Flu Vaccine
Fast-track recruitment has begun for a trial to investigate the safety of a vaccine against H5N1 avian influenza, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced today. Sites in Rochester, NY, Baltimore and Los Angeles will enroll a total of 450 healthy adults. The clinical sites are part of the NIAID-sponsored V...Experimental vaccine protects lab animals against several strains of H5N1
Nations are preparing to stockpile vaccines against H5N1, the strain of influenza virus that experts fear could cause the next flu pandemic. But will these vaccines remain effective as the virus mutates? Researchers present good news in the July 15 issue of The Journal of Infectious Diseases, now available online. Elena Govorkova, MD, PhD, Robert G. Webster, PhD, and coworkers at St. Jude...Experimental shingles vaccine proves effective in nationwide study
In one of the largest adult vaccine clinical trials ever, researchers have found that an experimental vaccine against shingles (zoster vaccine) prevented about half of cases of shingles--a painful nerve and skin infection--and dramatically reduced its severity and complications in vaccinated persons who got the disease. The findings appear in the June 2 issue of The New England Journal of Medicin...Experimental vaccine protects nonhuman primates when given after exposure to Marburg virus
Using multi-disciplinary analysis that included cognitive, neurophysiologic, virologic, and molecular techniques, the team found both a low-level viral infection in the brain and immune cells that had infiltrated the brain in order to protect against the virus. "As in the rest of the body, in the brain immune cells achieve a level of control of the virus, but are unable to clear the infec...Experimental TB drug effective against resistant and latent mycobacterium tuberculosis
An experimental tuberculosis drug may be effective against not only multi drug-resistant forms of the disease but could also be the first compound to treat the latent stage of infection as well. Researchers report their results today at the 2006 ASM Biodefense Research Meeting. "The class of which this compound is the lead has a very different mechanism of action from any other drug curr...Experimental treatment for Ebola Virus Shows promising results in mice
Scientists at the Center for Disease Control and Prevention (CDC) in Atlanta, Georgia, have said that an experimental treatment for the deadly Ebola virus has shown promising results in mice. In the study, researchers led by Dr. Manish Gupta took antibodies from the immune systems of mice that had survived infection with the deadly Ebola virus and injected them into other Ebola-free mice...Experimental drug to fight flu
RECENT research has shown that new compounds developed for preventing and treating the flue have shown promise in animal studies, and may require only one dose to be effective.// The compounds, known collectively as multimeric zanamivir, are based on the existing flu drug relenza, or zanamivir, which the U.S. Food and Drug administration approved in 1999 for treating influenza A and B. R...FDA approves Phase 0 trial which tests experimental drugs on humans
Good news for researchers has FDA has approved testing of small quantities of experimental drugs in human beings. Approval of small quantity drug clinical trial will be very helpful for researchers to// understand the path of the drug in the body and its efficacy if the drug is proved effective in small quantities researchers can proceed with a phase I clinical trial. Researchers feel...Experimental vaccine for shingles is effective
Researchers have discovered a newer form of chicken pox vaccine to// effectively control the painful condition called shingles. Shingles (also known as herpes zoster) is the condition that gets symptoms of rashes or blisters on the skin, along with sensations of burning pain, tingling, and numbness on the area. There may be fever with chills, headache or upset stomach. The infection i...Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Trophos Describes Identification, Characterization and BroadNeuroprotective Properties of TRO19622 in Journal of Pharmacologyand Experimental Therapeutics Neurodegenerative Disease Specialists Publish Details of a NovelDrug Candidate for ALS That Targets Mitochondrial Proteins MARSEILLE, June 19th, 2007 - Trophos SA, a biopharmaceuticalcompany specializing in the discovery an...Alnylam Reports Results of Human Experimental Infection Model with Respiratory Syncytial Virus
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 7, 2007 - AlnylamPharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeuticscompany, presented data from its experimental infection study atthe 2007 Pediatric Academic Societies' (PAS) Annual Meeting beingheld in Toronto. This study represents an important component ofthe company's clinical development program for ALN-RSV01, an RNAitherapeutic fo...